One or Two Immune Checkpoint Inhibitors?

The combination of ipilimumab and nivolumab was evaluated versus standard treatments in melanoma and lung cancer. Analysis of these trials highlights the differences in outcomes and potential predictive biomarkers across tumor types as well as the multiple remaining questions concerning the optimal...

Full description

Saved in:
Bibliographic Details
Published inCancer cell Vol. 36; no. 6; pp. 579 - 581
Main Authors Robert, Caroline, Lanoy, Emilie, Besse, Benjamin
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 09.12.2019
Subjects
Antibodies, Monoclonal - therapeutic use
Antineoplastic Agents - therapeutic use
Antineoplastic Combined Chemotherapy Protocols
Humans
Ipilimumab - therapeutic use
Lung Neoplasms - drug therapy
Lung Neoplasms - immunology
Melanoma - drug therapy
Melanoma - immunology
Online AccessGet full text

Cover

More Information
Summary:The combination of ipilimumab and nivolumab was evaluated versus standard treatments in melanoma and lung cancer. Analysis of these trials highlights the differences in outcomes and potential predictive biomarkers across tumor types as well as the multiple remaining questions concerning the optimal use of immune checkpoint inhibitors. The combination of ipilimumab and nivolumab was evaluated versus standard treatments in melanoma and lung cancer. Analysis of these trials highlights the differences in outcomes and potential predictive biomarkers across tumor types as well as the multiple remaining questions concerning the optimal use of immune checkpoint inhibitors.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1535-6108
1878-3686
DOI:10.1016/j.ccell.2019.11.005